argenx SE announced it will regain worldwide rights to its anti-CD70 antibody cusatuzumab from Cilag GmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Interim data from the Phase 1b ELEVATE trial support continued development in acute myeloid leukemia (AML) and argenx plans to evaluate options to enable a path forward.
“We have valued the productive collaboration with Janssen that has advanced our understanding of cusatuzumab and its role in AML biology. Together we have generated clinical and translational data that have optimized the dose of cusatuzumab and further characterized its effect on cells in the bone marrow,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “We set our target high with the ELEVATE trial, recognizing that cusatuzumab would have to add benefit to an already-established combination regimen. We believe these interim data show that cusatuzumab could be meaningful to AML patients. We plan to evaluate all alternatives to advance cusatuzumab on behalf of the AML community, while maintaining our focus on our priorities – the launch of efgartigimod and the development of our autoimmune pipeline.”
The ongoing Phase 1b ELEVATE trial is evaluating cusatuzumab in combination with venetoclax and azacitidine in newly-diagnosed, elderly patients with AML. The intent-to-treat (ITT) population included 44 patients. Early efficacy analyses conducted in all evaluable patients (N=42) after ongoing patients had completed at least two disease evaluations showed:
- Complete remission (CR) was observed in 48% (20/42), composite complete remission (CRc) including CRs with incomplete hematologic recovery was observed in 81% (34/42), and overall response rate (ORR) in 93% (39/42) of the evaluable population.
- Cusatuzumab was observed to be well-tolerated and the safety profile was consistent with prior studies.
- ELEVATE is ongoing; complete results will be presented in an upcoming peer-reviewed forum.
Additionally, ongoing translational research on AML patient bone marrow samples from the Phase 2 CULMINATE trial show a decrease in primitive, monocytic-like blasts and leukemic stem cells, and an increase in normal myeloid cells, following treatment with cusatuzumab and azacitidine.
The collaboration and licensing agreement between argenx and Janssen was initiated in 2018 to develop cusatuzumab to treat AML and myelodysplastic syndromes (MDS). Under the terms of the agreement, argenx received $300 million in an upfront payment, approximately $200 million in an equity investment from Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and $25 million in milestone payments to date. argenx was notified of Janssen’s decision to discontinue the collaboration agreement during a regularly scheduled steering committee meeting on June 4, 2021. Following termination of the collaboration, argenx can elect that Janssen operationally support the treatment and follow-up of patients enrolled in ongoing cusatuzumab clinical trials.
